304 related articles for article (PubMed ID: 6177320)
21. Cyclic nucleotide phosphodiesterases from rat anterior pituitary. Characterization of multiple forms and regulation by protein activator and Ca+.
Azhar S; Menon KM
Eur J Biochem; 1977 Feb; 73(1):73-82. PubMed ID: 190011
[TBL] [Abstract][Full Text] [Related]
22. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
Butt NM; Saeed SA; Collier HO
Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
[No Abstract] [Full Text] [Related]
24. The metabolism of cyclic nucleotides in the guinea-pig pancreas. Cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase.
Methven P; Lemon M; Bhoola K
Biochem J; 1980 Feb; 186(2):491-8. PubMed ID: 6246887
[TBL] [Abstract][Full Text] [Related]
25. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
Kuo JF; Shoji M; Brackett NL; Helfman DM
J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
[TBL] [Abstract][Full Text] [Related]
26. Irreversible inhibition of calmodulin-sensitive cyclic nucleotide phosphodiesterase.
Sullivan TA; Duemler BH; Kuttesch NJ; Keravis TM; Wells JN
J Cyclic Nucleotide Protein Phosphor Res; 1986; 11(5):355-64. PubMed ID: 2442214
[TBL] [Abstract][Full Text] [Related]
27. Differences in the association of calmodulin with cyclic nucleotide phosphodiesterase in relaxed and contracted arterial strips.
Saitoh Y; Hardman JG; Wells JN
Biochemistry; 1985 Mar; 24(7):1613-8. PubMed ID: 2988604
[TBL] [Abstract][Full Text] [Related]
28. Methylxanthine inhibitors of phosphodiesterases.
Wells JN; Miller JR
Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
[No Abstract] [Full Text] [Related]
29. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
30. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase.
Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE
Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820
[TBL] [Abstract][Full Text] [Related]
31. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Silver PJ; Hamel LT; Perrone MH; Bentley RG; Bushover CR; Evans DB
Eur J Pharmacol; 1988 May; 150(1-2):85-94. PubMed ID: 2841146
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
33. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.
Frossard N; Landry Y; Pauli G; Ruckstuhl M
Br J Pharmacol; 1981 Aug; 73(4):933-8. PubMed ID: 6168323
[TBL] [Abstract][Full Text] [Related]
34. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
Walker KA; Boots MR; Stubbins JF; Rogers ME; Davis CW
J Med Chem; 1983 Feb; 26(2):174-81. PubMed ID: 6298424
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the different cyclic nucleotide phosphodiesterase isoforms separated from rat brain by flavonoid compounds.
Picq M; Dubois M; Prigent AF; Némoz G; Pacheco H
Biochem Int; 1989 Jan; 18(1):47-57. PubMed ID: 2541724
[TBL] [Abstract][Full Text] [Related]
36. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
Elks ML; Manganiello VC
Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
Némoz G; Prigent AF; Picq M; Pacheco H
Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
[No Abstract] [Full Text] [Related]
38. Cyclic nucleotide phosphodiesterase. Partial purification and characterization of a high affinity enzyme activity from human lung tissue.
Bergstrand H; Lundquist B; Schurmann A
J Biol Chem; 1978 Mar; 253(6):1881-91. PubMed ID: 204635
[TBL] [Abstract][Full Text] [Related]
39. Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments.
Jackson BA; Edwards RM; Dousa TP
Kidney Int; 1980 Oct; 18(4):512-8. PubMed ID: 6164816
[No Abstract] [Full Text] [Related]
40. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain.
Levin RM; Weiss B
Mol Pharmacol; 1976 Jul; 12(4):581-9. PubMed ID: 183095
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]